pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Lead Program · news · pharmadog
← back to Lead Program
News mentioning Lead Program
26
stories
3d
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
8d
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
fiercebiotech
10d
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
biopharma dive
10d
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
11d
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
fiercebiotech
15d
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
biospace
15d
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
16d
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
stat
21d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
21d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
21d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
22d
Caldera, Vidya add to recent flurry of biotech mergers
biopharma dive
27d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 17, 26
Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jul 14, 26
Draig nets $65M to advance depression drug aimed at rebuilding synapses
endpoints
Jun 12, 26
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says
biopharma dive
Jun 8, 26
City banks nearly $100M for next-gen RNAi drugs
biopharma dive
Jun 8, 26
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
biopharma dive
May 8, 26
Odyssey, on second try, snags $279M in an IPO
biopharma dive
May 5, 26
Cytospire hauls in $83M for a new type of T cell engager
biopharma dive
Apr 22, 26
Merck adds to pharma’s AI push; Roche details MS drug results
biopharma dive
Dec 22, 25
Fierce Biotech Fundraising Tracker '26: Abcuro secures $66M; InduPro assembles $77M
fiercebiotech
